Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 4/2016

01-12-2016 | Original Article

Differential Expression of T-bet and GATA3 in Egyptian Children with Idiopathic Thrombocytopenic Purpura

Authors: Amira Ahmed Hammam, Dina Ahmed Ezzat, Marwa Hamed Abd Elwahab

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 4/2016

Login to get access

Abstract

GATA3 and T-box (T-bet) expressed in T-cells are transcriptional factors that play a critical role in development of Th2 and Th1 immunity respectively. GATA3 is expressed during Th2 differentiation and T-bet is expressed exclusively in Th1 cells. Thus, a balance between GATA3 and T-bet is believed to control Th2/Th1 polarization. Therefore, the high expression of T-bet and low expression of GATA3 indicate the existence of Th1 polarization in children with acute immune thrombocytopenic purpura (ITP). This might be related to the regulation of T-bet and GATA3. The objective of this work was to study the expression of transcriptional factors T-bet and GATA3 m RNA in children with idiopathic thrombocytopenic purpura and correlate it with clinical findings, laboratory findings, and outcome of patients. In this study the expression of T-bet and GATA3 genes was analysed in 20 normal healthy individuals and 40 children with ITP (20 acute and 20 persistent) using reverse transcriptase polymerase chain reaction to investigate a possible relation, association or correlation with the type of ITP and prognosis. T-bet was expressed significantly in 60 % of acute ITP children (12/20) (P value 0.001) and not expressed in persistent ITP children (0/20), while GATA3 was expressed in 25 % of persistent ITP patients (5/20) (P value 0.017) and not expressed in acute ITP patients (0/20). Both genes were not detected in healthy controls. We concluded that the high expression of T-bet and the low expression of GATA3 indicate the existence of Th1 polarization in children with acute ITP. This might be related to the regulation of T-bet and GATA3. Intensive studies of abnormal cytokine profiles in ITP have led to cytokine therapies that exploit the effects of IFN-γ on Th2 cells, but such therapies are often ineffective to develop safe and effective therapeutic tools. Targeting specific molecules such as T-bet and GATA3 may be a novel therapeutic tool in ITP.
Literature
1.
Coopamah M, Garvey M, Freedman J, Semple J (2003) Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. Transfus Med Rev 17(1):69–80CrossRefPubMed
2.
Schwartz RS (2007) Immune thrombocytopenic purpura-from agony to agonist. N Engl J Med 357(22):2299–2301CrossRefPubMed
3.
4.
Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, Bussel JB (2005) Persistent immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 146:217–221CrossRefPubMed
5.
Arakawo S, Hatano Y, Katagiri K (2004) Differential expression of mRNA for Th1 and Th2 cytokine associated transcriptional factors and suppressors of cytokine signaling in peripheral blood mononuclear cells of patients with atopic dermatitis. Clin Exp Immunol 135(3):505–510CrossRef
6.
Afkarian M, Sedy JR, Yang J (2002) T-bet is a STAT1-induced regulator for IL-12 R expression in naïve CD4+ T-cells. Nat Immunol 3(6):549–557CrossRefPubMed
7.
Lugo-Villarino G, Maldonado-López R, Possemato R, Peñaranda C, Glimcher LH (2003) T-bet is required for optimal production of IFNγ and antigen-specific T-cell activation by dendritic cells. Proc Natl Acad Sci USA 100(13):7749–7754CrossRefPubMedPubMedCentral
8.
Lazarevic V, Chen X, Shim JH (2011) T-bet represses TH 17 differentiation by preventing Runx1-mediated activation of the gene encoding RORγt. Nat Immunol 12(1):96–104CrossRefPubMed
9.
Djuretic IM, Levanon D, Negreanu V, Groner Rao A, Ansel KM (2007) Transcription factors T-bet and RUNX3 cooperate to activate IFNγ and silence IL-4 in T helper type 1 cells. Nat Immunol 8(2):145–153CrossRefPubMed
10.
Zhu J, Guo L, Watson CJ, Hu-Li J, Paul WE (2001) STAT6 is necessary and sufficient for IL-4’s role in TH2 differentiation and cell expansion. J Immunol 166(12):7276–7281CrossRefPubMed
11.
Zhu J, Yamane H, Cote-Sierra J, Guo L, Paul WE (2006) GATA3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cellspecific factors. Cell Res 16(1):3–10CrossRefPubMed
12.
Usui T, Nishikomori R, Kitani A, Strober W (2003) GATA3 suppresses Th1 development by down-regulation of Stat4 and not through effects on IL-12Rβ2 chain or T-bet. Immunity 18(3):415–428CrossRefPubMed
13.
Rodeghiero F, Stasi R, Gernsheimer T et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children. Report from an international working group. Blood 113:2386–2393CrossRefPubMed
14.
Kuhen T (2013) Update of the international co-operative ITP study (ICIS)and on the pediatric and adult registry on persistent ITP(PARC ITP). Pediatr Blood Cancer 60:S15–S18CrossRef
15.
World Medical Association. Declaration of Helsinki (2008) Ethical principles for medical research involving human subjects. In: The 59th WMA General Assembly, Seoul, South Korea
16.
Cooper N, Bussel J (2006) The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 133(4):364–374CrossRefPubMed
17.
18.
19.
Breunis WB, van Mirre E, Bruin M et al (2008) Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 111(3):1029–1038CrossRefPubMed
20.
Ho IC, Glimcher LH (2002) Transription, initializing times for T cells. Cell 109(Suppl):S109–S120CrossRefPubMed
21.
Ouyang W, Ranganath SH, Weindel K et al (1998) Inhibition of Th1 development mediated by GATA-3 through an IL-4 independent mechanism. Immunity 9:745–755CrossRefPubMed
22.
Bian T, Yin K, Jin S et al (2006) Treatment of allergic airway inflammation and hyperresponsiveness by imiquimod modulating transcription factors T-bet and GATA-3. Chin Med J 119(8):640–648PubMed
23.
Rengarajan J, Szabos J, Glimcher LH (2000) Transcriptional regulation of Th1/Th2 polarization. Immunol Today 21:479–483CrossRefPubMed
24.
Lee GR, Fields PE, Flavell RA (2001) Regulation of IL-4 gene expression by distal regulatory elements and GATA3 at the chromatin level. Immunity 14:447–459CrossRefPubMed
25.
Zhang DH, Yang L, Ray A (1998) Differential responsiveness of the IL-5 & IL-4 genes to transcriptional factor GATA-3. J Immunol 161:3817–3821PubMed
26.
Finotto S, Neurath MF, Glickman JN et al (2002) Development of spontaneous air way changes consistent with human asthma in mice lacking T-bet. Science 295:336–338CrossRefPubMed
27.
Szabo DH, Sullivan BM, Stemmann C et al (2002) Distinct effects of T-bet in Th1 lineage commitment and IFN-production in CD4 and CD8 T cells. Science 295:338–342CrossRefPubMed
28.
Ren S-M, Zhang C-X, Li W-C (2010) Expression of T-bet and GATA3 in children with acute thrombocytopenic purpura. Chin J Contemp Pediatr 12(1):29–31
29.
Kawashima M, Miossec P (2005) Effect of treatment of rheumatoid arthritis with infliximab on IFNγ, IL4, T-bet, and GATA-3expression: link with improvement of systemic inflammation and disease activity. Ann Rheum Dis 64:415–418CrossRefPubMed
Metadata
Title
Differential Expression of T-bet and GATA3 in Egyptian Children with Idiopathic Thrombocytopenic Purpura
Authors
Amira Ahmed Hammam
Dina Ahmed Ezzat
Marwa Hamed Abd Elwahab
Publication date
01-12-2016
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 4/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-015-0625-z

Other articles of this Issue 4/2016

Indian Journal of Hematology and Blood Transfusion 4/2016 Go to the issue

Original Article

Clinical Characteristics and Prognostic Factors in Hemophiliacs with Intracranial Hemorrhage: A Single-Center, Retrospective Experience

Original Article

Proliferation and Angiogenesis Using Immunohistochemistry in Prognosticating Multiple Myeloma

Editorial

Molecular Genetic Diagnosis of the Inherited Bleeding Disorders: Are We Close to the Perfect Test?

Images

Knuckle Pigmentation: A Clue to Systemic Illness

Correspondence

The Mysterious Story of Brown Blood and High Saturation Gap

Correspondence

Autoimmune Haemolytic Anaemia in a Child Due to Chickenpox
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits